Suchen
Can Fite Biopharma Ltd
CANFZur Watchlist hinzufügen
4.700USD
+1.730+58.25%
Handelsschluss 07/01, 16:00（ET）Kurse um 15 Minuten verzögert
41.02KMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Can Fite Biopharma Ltd Unternehmen
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Can Fite Biopharma Ltd Informationen
BörsenkürzelCANF
Name des UnternehmensCan Fite Biopharma Ltd
IPO-datumSep 22, 2005
CEOFishman (Pnina)
Anzahl der mitarbeiter5
WertpapierartDepository Receipt
GeschäftsjahresendeSep 22
Addresse10 Bareket Street, Kiryat Matalon
StadtPETAH TIKVA
BörseNASDAQ OMX – NASDAQ Basic Amex
LandIsrael
Postleitzahl49170
Telefon97239241114
Websitehttps://www.canfite.com/
BörsenkürzelCANF
IPO-datumSep 22, 2005
CEOFishman (Pnina)
Führungskräfte von Can Fite Biopharma Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Pnina Fishman, Ph.D.
Dr. Pnina Fishman, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ilan Cohen
Dr. Ilan Cohen
Chairman of the Board
Chairman of the Board
--
--
Mr. Motti Farbstein
Mr. Motti Farbstein
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. Abraham Sartani, M.D.
Dr. Abraham Sartani, M.D.
Independent Director
Independent Director
--
--
Mr. Guy Regev
Mr. Guy Regev
Independent Director
Independent Director
--
--
Dr. Sari Fishman, Ph.D.
Dr. Sari Fishman, Ph.D.
Vice President - Business Development
Vice President - Business Development
--
--
Mr. Yoseph Borenstein
Mr. Yoseph Borenstein
Director
Director
--
--
Mr. Yaacov Goldman
Mr. Yaacov Goldman
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Pnina Fishman, Ph.D.
Dr. Pnina Fishman, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ilan Cohen
Dr. Ilan Cohen
Chairman of the Board
Chairman of the Board
--
--
Mr. Motti Farbstein
Mr. Motti Farbstein
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. Abraham Sartani, M.D.
Dr. Abraham Sartani, M.D.
Independent Director
Independent Director
--
--
Mr. Guy Regev
Mr. Guy Regev
Independent Director
Independent Director
--
--
Dr. Sari Fishman, Ph.D.
Dr. Sari Fishman, Ph.D.
Vice President - Business Development
Vice President - Business Development
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Can Fite Biopharma Ltd?
Die fünf größten Anteilseigner von Can Fite Biopharma Ltd sind: Dr. Sari Fishman, Ph.D.
Wie viele Institutionen halten Anteile an Can Fite Biopharma Ltd (CANF)?
Mit Stand vom 2026Q1 halten 28 Institutionen Anteile an Can Fite Biopharma Ltd, mit einem Gesamtmarktwert von etwa 32.13K, was 1.50% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -81636.00 gestiegen.